• Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Do you have psoriasis and are you about to start therapy with etanercept?

Subjects age 18-80 with moderate-to-severe psoriasis may be eligible to participate in a research study investigating the degree of inflamed coronary artery and aortic atherosclerotic plaque by cardiac FDG-PET, as well as any response of plaque inflammation to etanercept (enbrel) therapy. Participants will be monitored over the course of the first three months after they are initiated on etanercept 50 mg SC once or twice weekly by their dermatologists for psoriasis treatment. Participation in this study requires an initial screen visit to determine eligibility, followed by 5 outpatient visits over 3 months for eligible subjects. Compensation up to $500 is provided. For more information call Allison Han at (617) 724-0248, Program in Nutritional Metabolism, Massachusetts General Hospital.


Are you a healthy adult without psoriasis?

Subjects age 18-80 who do not have psoriasis may be eligible to participate as control subjects in a research study investigating the degree of inflamed coronary artery and aortic atherosclerotic plaque by cardiac FDG-PET in subjects with or without psoriasis. Participation in this study requires an initial screen visit to determine eligibility, followed by 2 outpatient visits over approximately 1 month for eligible subjects. Compensation up to $125 is provided. For more information call Allison Han at (617) 724-0248, Program in Nutritional Metabolism, Massachusetts General Hospital.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – Steven Grinspoon, MD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Allison M Han
Email  – amhan@partners.org
Phone  – 617-724-0248